Obesity/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials
- 25 January 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 39 (2) , 92-97
Abstract
Purpose of review: Heart failure with preserved ejection fraction (HFpEF) is a leading and growing cause of morbidity and mortality globally. Of the various phenotypes identified, the obesity (or cardiometabolic) phenotype appears to be most common. The purpose of this review is to provide the clinician with an abridged understanding of recent developments that have elucidated obesity/visceral adiposity as a central mechanism linking inflammation/immune dysregulation to the development of the HFpEF syndrome. Recent clinical trials examining the efficacy of pharmacological treatments that target obesity in HFpEF will also be discussed. Recent findings: Recent data indicate that visceral adiposity and insulin resistance in HFpEF serve as key mechanisms driving inflammation and immune dysregulation, which play a critical role in the development of cardiac stiffness, diastolic dysfunction and fibrosis in HFpEF. In obesity, alterations in macrophage polarization, changes in innate and adaptive immune systems and altered myocardial energetics promote metabolic inflammation in HFpEF. Finally, emerging data suggest that inflammatory biomarkers, specifically, IL-6, may provide useful information about HFpEF severity and symptom burden in obesity. Summary: The obesity phenotype of HFpEF is seen in upward of 80% with HFpEF. Obesity is not just a bystander, but plays an essential role in the pathobiology and clinical course of HFpEF. Targeting overweight/obesity in HFpEF with GLP-1 receptor agonists holds promise in these patients.Keywords
This publication has 38 references indexed in Scilit:
- Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure With Preserved Ejection FractionJACC: Heart Failure, 2020
- Metabolic inflammation in heart failure with preserved ejection fractionCardiovascular Research, 2020
- Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection FractionJACC: Heart Failure, 2020
- Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fractionEuropean Heart Journal, 2018
- IL-1 Blockade in Patients With Heart Failure With Preserved Ejection FractionCirculation: Heart Failure, 2018
- Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection FractionJACC: Heart Failure, 2018
- Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection FractionCirculation, 2017
- Epidemiology of heart failure with preserved ejection fractionNature Reviews Cardiology, 2017
- Impact of General and Central Adiposity on Ventricular-Arterial Aging in Women and MenJACC: Heart Failure, 2014
- Long-Term Trends in the Incidence of and Survival with Heart FailureNew England Journal of Medicine, 2002